Dinox® (Tablets) Instructions for Use
ATC Code
R06AX26 (Fexofenadine)
Active Substance
Fexofenadine (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Histamine H1-receptor blocker. Antiallergic drug
Pharmacotherapeutic Group
Antiallergic agent – H1-histamine receptor blocker
Pharmacological Action
Histamine H1-receptor blocker. Fexofenadine is a pharmacologically active metabolite of terfenadine. It does not have a sedative effect.
The antihistamine effect appears within 1 hour, reaches a maximum in 6 hours, and lasts for 24 hours. No tolerance was observed after 28 days of administration.
It has been established that when taken orally in the dose range from 10 mg to 130 mg, the efficacy of fexofenadine is dose-dependent.
Pharmacokinetics
After oral administration, it is rapidly absorbed from the gastrointestinal tract. Tmax is reached within 1-3 hours. The mean Cmax after a 180 mg dose is approximately 494 ng/ml, and after a 120 mg dose – 427 ng/ml. Plasma protein binding is 60-70%. T1/2 after multiple doses is 11-15 hours. It is excreted in breast milk. 5% of the dose undergoes partial extrahepatic metabolism. It is excreted mainly with bile (80%), 10% is excreted by the kidneys unchanged.
Indications
Relief of symptoms associated with seasonal allergic rhinitis, symptomatic treatment of chronic urticaria.
ICD codes
| ICD-10 code | Indication |
| J30.1 | Allergic rhinitis due to pollen |
| L50 | Urticaria |
| ICD-11 code | Indication |
| CA08.00 | Allergic rhinitis due to pollen |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For adults and children over 12 years of age, administer 120 mg to 180 mg orally once daily.
Take the tablet with water. For consistent absorption, administer the dose separately from antacid medications containing aluminum or magnesium hydroxide; maintain a minimum 2-hour interval.
For patients with moderate to severe renal impairment, initiate therapy at the lower end of the dosage range. Exercise caution and consider dose adjustment based on clinical response and tolerability.
The total daily dose must not exceed 180 mg. Do not crush or chew the tablet. The duration of treatment is determined by the physician based on the indication and symptom control.
Adverse Reactions
The following are possible headache, drowsiness, dizziness, fatigue, nausea, lethargy, increased fatigue.
Contraindications
Pregnancy, lactation period, children under 6 years of age, hypersensitivity to fexofenadine.
Use in Pregnancy and Lactation
Fexofenadine is contraindicated for use during pregnancy and during the lactation period (breastfeeding).
Fexofenadine passes into breast milk. If it is necessary to use fexofenadine during lactation, the issue of discontinuing breastfeeding should be decided.
Use in Hepatic Impairment
Use with caution in patients with hepatic insufficiency.
Use in Renal Impairment
Use with caution in patients with renal insufficiency.
Pediatric Use
Use of the drug in children under 6 years of age is not recommended.
Geriatric Use
Use with caution in elderly patients.
Special Precautions
Use with caution in elderly patients, in patients with renal or hepatic insufficiency.
The efficacy and safety of fexofenadine in children under 6 years of age have not been studied.
Effect on the ability to drive vehicles and mechanisms
Based on the pharmacodynamic profile and known side effects, it can be assumed that the effect of fexofenadine on the ability to drive a car and engage in activities requiring increased concentration is unlikely. Objective studies have shown that Fexofenadine does not have a significant effect on CNS functions. Nevertheless, it is recommended to check the individual reaction before driving a car or engaging in other potentially hazardous activities.
Drug Interactions
Fexofenadine is not biotransformed in the liver and therefore does not interact with other drugs undergoing hepatic metabolism.
It has been shown that with the simultaneous use of fexofenadine with erythromycin or ketoconazole, the plasma concentration of fexofenadine increases by 2-3 times, which is apparently associated with an increase in absorption from the gastrointestinal tract and with a reduction in either bile excretion or gastrointestinal secretion. No changes in the QT interval were observed.
When taking antacids containing aluminum or magnesium 15 minutes before taking fexofenadine, a decrease in its bioavailability was observed, most likely due to binding in the gastrointestinal tract. The recommended time interval between taking fexofenadine and antacids containing aluminum or magnesium hydroxide is 2 hours.
Does not interact with omeprazole, with drugs metabolized in the liver.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Film-coated tablets, 120 mg: 10 pcs.
Marketing Authorization Holder
Dr. Reddy's Laboratories Ltd. (India)
Dosage Form
| Dinox® | Film-coated tablets, 120 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets pink, oval, biconvex, with an imprint ” FXF ” on one side, and “120” on the other; on the cross-section – a core of white or almost white color.
| 1 tab. | |
| Fexofenadine hydrochloride | 120 mg |
Excipients: cellulose – 261.13 mg, mannitol – 83.34 mg, corn starch – 67.67 mg, croscarmellose sodium – 48 mg, colloidal silicon dioxide – 13.33 mg, magnesium stearate – 7.53 mg.
Film coating composition: opadry pink (hypromellose – 67.995%, titanium dioxide (E171) – 25.055%, macrogol-400 – 6.8%, iron oxide black dye (E172) – 0.036%, brilliant red dye (E129) – 0.114%) – 18 mg.
10 pcs. – PVC/PE/PVDC/aluminum blisters (1) – cardboard packs.
Film-coated tablets, 30 mg: 10 pcs.
Marketing Authorization Holder
Dr. Reddy's Laboratories Ltd. (India)
Dosage Form
| Dinox® | Film-coated tablets, 30 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
| Film-coated tablets | 1 tab. |
| Fexofenadine hydrochloride | 30 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
Film-coated tablets, 60 mg: 10 pcs.
Marketing Authorization Holder
Dr. Reddy's Laboratories Ltd. (India)
Dosage Form
| Dinox® | Film-coated tablets, 60 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
| Film-coated tablets | 1 tab. |
| Fexofenadine hydrochloride | 60 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
Film-coated tablets, 180 mg: 10 pcs.
Marketing Authorization Holder
Dr. Reddy's Laboratories Ltd. (India)
Dosage Form
| Dinox® | Film-coated tablets, 180 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
| Film-coated tablets | 1 tab. |
| Fexofenadine hydrochloride | 180 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
Belosalic, lotion solution for external use spray 100ml
No-spa pills 40mg, 64pcs
Arbidol, capsules 100mg, 40pcs
Noopept, pills 10mg, 50pcs
Fenotropil pills 100mg, 60pcs
Kagocel pills 12mg, 30pcs
OKI, sachets 80mg 2g, 12pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Mildronate capsules 500mg, 90pcs
Nootropil pills 800mg, 30pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Picamilon pills 50mg, 60pcs
Phenibut-Vertex pills 250mg, 20pcs
Actovegin pills 200mg, 50pcs
Belosalic, ointment, 30g
Ingavirin capsules 90mg, 10pcs 